Product Images Donepezil Hydrochloride

This appears to be a table or graph displaying changes in ADAS-cog (Alzheimer's Disease Assessment Scale - cognitive subscale) scores from baseline over the course of a drug treatment. The drug being evaluated is donepezil, with both 5mg/day and 10mg/day doses being tested, along with a placebo. The data appears to be broken down by weeks of treatment (6, 12, and 18), and includes values for clinical improvement and decline. There is no additional context provided.*

This text appears to be a table displaying the conversion of a dose of Donepezil from 10mg per day to 23mg per day, with some additional data points and a rating scale labeled as CIBIC-plus. It is difficult to determine the context and purpose of this data without additional information.*

The text describes a chart showing the cumulative percentage of patients for Donepezil 10 mg/day, Donepezil 5 mg/day, and Placebo. There is also a graph showing the change in ADAS cog, with treatment groups indicated. The percentages for patients on Donepezil 10 mg/day and Donepezil 5 mg/day are provided for certain measure points. The graph also shows the change from baseline on a scale of 0 to 15.*

This appears to be a chart or graph showing the percentage of patients in different treatment groups (Donepezil 10 mg/day, Donepezil 5 mg/day, and Placebo) evaluated by the CIBIC-plus Rating. The rating scale ranges from "Markedly Improved" to "Markedly Worse" with varying levels of improvement or change in between.*

This is a table showing the cumulative percentage of patients in a treatment group for a study on the effects of Donepezil on Alzheimer's disease. The table also includes changes in ADAS-cog scores for patients taking different doses of Donepezil versus a placebo. There are three treatment groups: Donepezil 10mg/day, Donepezil 5mg/day, and Placebo. The table shows the percentage change in ADAS-cog scores for each group at three different time points: baseline, 4 points, and 7 points.*

This appears to be a prescription dosage information for Donepezil, a medication commonly used to treat Alzheimer's disease. It includes dosing information for both 5mg and 10mg daily pills. The last line mentions a "CIBIC-plus rating", which is a standardized measurement used to assess the severity of cognitive decline in Alzheimer's patients.*

The text represents a comparison of clinical trial data between the drug Donepezil (administered at a dosage of 10mg/day) and a placebo. The data presented in the table measures SIB (Severe Impairment Battery) change from baseline over a period of time, but the table is not readable due to poor formatting and lack of context.*